Drug · CHEMBL31
GATIFLOXACIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. GATIFLOXACIN. Drugs and targets, record CHEMBL31. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL31
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
AM-1155, BMS-206584-01, BMS-20658401, Gatiflo, Gatifloxacin (sesquihydrate), Gatifloxacin anhydrous, Gatifloxacin hydrate, Gatifloxacin sesquihydrate, Gatifloxacine, Gatifloxacino, NSC-758701, PD-135432, Zymer
- ChEMBL
- Open Targets' highest stage
- Approval, for 9 of its 14 diseases, from ATC, DailyMed, PMDA and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases14
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 14Source Open Targets
See all 14 diseasesTrials28
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00518089 | A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis | Phase 3 | 859 | 2011-11-30 | gatifloxacin | Its name | ClinicalTrials.gov |
| NCT00509873 | A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis | Phase 3 | 578 | 2011-11-30 | gatifloxacin | Its name | ClinicalTrials.gov |
| NCT00464438 | A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis | Phase 4 | 171 | 2011-09-21 | gatifloxacin | Its name | ClinicalTrials.gov |
| NCT02980523 | Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) | Phase 2 | 150 | 2019-02-15 | gatifloxacin | Its name | ClinicalTrials.gov |
| NCT00410891 | Topical Antibiotics and Intravitreous Injections | Phase 4 | 129 | 2014-06-12 | gatifloxacin | Its name | ClinicalTrials.gov |
| NCT00824070 | Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects | Phase 1 | 105 | 2010-10-29 | gatifloxacin | Its name | ClinicalTrials.gov |
| NCT00396084 | Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis | Phase 1/2 | 70 | 2009-06-25 | gatifloxacin | Its name | ClinicalTrials.gov |
| NCT00874887 | A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms | Phase 4 | 66 | 2011-12-19 | gatifloxacin | Its name | ClinicalTrials.gov |
| NCT00350363 | One Hour Preoperative Gatifloxacin | Phase 4 | 60 | 2015-01-29 | gatifloxacin | Its name | ClinicalTrials.gov |
| NCT03696342 | Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. | Phase 3 | 46 | 2021-08-24 | gatifloxacin | Its name | ClinicalTrials.gov |
1 to 10 of 28
See all 28 trialsComparisons in its trials14
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Gatifloxacin 0.5% Eye Drops vs Placebo Eye Drops: serious adverse events | 2 of 429 | 0 of 427 | 856 | NCT00518089 | Trial comparisons |
| Gatifloxacin 0.5% Eye Drops vs Placebo Eye Drops: serious adverse events | 0 of 288 | 1 of 289 | 577 | NCT00509873 | Trial comparisons |
| Gatifloxacin 0.3% vs Moxifloxacin 0.5%: serious adverse events | 0 of 84 | 1 of 86 | 170 | NCT00464438 | Trial comparisons |
| Vigamox® vs Zymar®: serious adverse events | 0 of 32 | 0 of 34 | 66 | NCT00874887 | Trial comparisons |
| LessDrops vs Standard of Care: deaths from any cause | 0 of 33 | 0 of 33 | 66 | NCT03578276 | Trial comparisons |
| LessDrops vs Standard of Care: serious adverse events | 0 of 33 | 0 of 33 | 66 | NCT03578276 | Trial comparisons |
| PRO-157 vs Zymar: deaths from any cause | 0 of 23 | 0 of 23 | 46 | NCT03696342 | Trial comparisons |
| PRO-157 vs Zymar: serious adverse events | 0 of 23 | 0 of 23 | 46 | NCT03696342 | Trial comparisons |
| PRO-157 vs Zymar: Presence of Clinical Remission Defined as Absence of Hyperemia and Secretion by the Final Visit | 15 of 22 | 19 of 23 | 45 | NCT03696342 | Trial comparisons |
| PRO-157 vs Zymar: Presence of Bacterial Eradication Compared to Baseline Culture Results | 19 of 22 | 22 of 23 | 45 | NCT03696342 | Trial comparisons |
1 to 10 of 14
See all 14 comparisons in its trialsPapers from its trials13
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL31
GET https://conductscience.org/api/drugs/v1/CHEMBL31/trials?page=2